Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
An initial take on the Agency's proposal for biosimilars
February 29, 2012
By: Tim Clark
(Expert Opinion posts reflect the views of their authors, and not the views of Contract Pharma. If you’d like to comment on Mr. Cook’s post, log in and start a discussion in our new Comments section, or e-mail us at contractpharma@rodpub.com) FDA has issued three draft guidance documents on how to demonstrate that a biological product is biosimilar to an FDA-approved biological product using the abbreviated pathway established by the Public Health Service Act. First Draft Guidance: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product FDA has outlined a risk-based totality-of-the-evidence approach, similar to that developed by the European Medicines Agency (EMA) . The extent of the analyses and testing that will be required to demonstrate biosimilarity of a protein product will be determined on a product-specific basis. The FDA expects the reference product to have been licensed by them; however, in contrast to the EMA, the FDA has left open the possibility of bridging to the U.S.-licensed product. Similar to the EMA, the FDA recommends a step-wise approach, emphasising that the basis of every biosimilar development program is extensive structural and functional characterization comparing the biosimilar and the reference products. FDA proposes that data from each step — broadly categorized as structural analysis, functional analysis, animal data and clinical studies — should be evaluated to determine the extent to which “there is residual uncertainty” regarding a demonstration of biosimilarity between the biosimilar and reference products. At each stage the data is reviewed and used to identify next steps to address that uncertainty. The extent to which it is necessary to perform animal toxicity studies is determined after a thorough review of data from structural and functional analyses. EMA has sought to limit the extent of animal toxicity testing and the FDA leaves plenty of room to justify why extensive testing is not warranted. The extent of the clinical program depends on the accumulated data, in particular the structural and functional characterization. Nevertheless, it is reasonably clear that human PK and PD and immunogenicity studies will be fundamental to any biosimilar development and that evidence of comparable efficacy and safety will be required for complex protein products such as monoclonal antibodies. What is noteworthy is that FDA discusses circumstances where non-inferiority rather than equivalence study designs would be appropriate, stating that these would generally allow for a smaller sample size. They also provide guidance on the opportunity for extrapolation across indications. In the summary, the FDA guidance provides general pointers but still leaves many questions unanswered for biosimilar developers. It is hoped that these open questions will eventually be addressed in product-specific guidance. The last sentence of the document is probably the main take-home message: “FDA anticipates that early discussions with FDA about product development plans and about the appropriate scientific justifications will facilitate biosimilar development.” Second Draft Guidance: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product This provides an overview of analytical factors that may be relevant to evaluating the similarity of a biosimilar product and a reference product. Similar to other biosimilar guidance, the importance of extensive structural (physicochemical) and functional (biological activity) characterization is emphasized. The guidance is broad, considering factors ranging from the expression system used to the stability of the final product. As with the previous guidance, it stresses a “totality of data” approach, noting that all data should be evaluated to assess the potential impact of any differences between the biosimilar and the reference products on efficacy and safety. It highlights the complexity of these types of drug product, the need for highly sophisticated analytical testing and interpretation, and the importance of the higher order structure and fine detail that may only be discernible with appropriate, clinically relevant, in vitro biological assays. FDA recognizes scientific advances, noting that a “fingerprint”-like analysis of therapeutic protein products will continue to develop and that such advances may allow for a more selective and targeted approach to animal and/or clinical testing. Finally, FDA states that it is still considering what type of information would be sufficient to show that a biological product is interchangeable with the reference product. Third Draft Guidance: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 The final section provides answers to frequent asked questions (FAQs) regarding FDA’s interpretation of the BPCI Act. The draft guidance will be posted on FDA’s website and will be updated as appropriate.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !